

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Pathogenesis and Cure (X6)

Scientific Organizers: Robert F. Siliciano, Carine M. Van Lint and Romas Geleziunas
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

HIV Vaccines (X5)

Scientific Organizers: Persephone Borrow, Georgia D. Tomaras and Rogier W. Sanders
March 22-26, 2020 • Keystone Resort • Keystone, CO, USA
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

Global Health Travel Award Deadline: October 22, 2019 / Discounted Abstract & Scholarship Deadline: November 20, 2019 / Abstract Deadline: December 18, 2019 / Discounted Registration Deadline: January 23, 2020

SUNDAY, MARCH 22

Arrival and Registration

MONDAY, MARCH 23

Welcome and Keynote Session (Joint)

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Accelerating HIV Vaccine Development to Prevent HIV Infection
Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
I am Nothing Without You: The Romance of T and B Cells and Prospects for HIV Prevention and Cure

Breakthrough Technologies (Joint)

Mark M. Davis, Stanford University School of Medicine, USA
Novel Approaches for T Cell Repertoire Analysis
Guillaume J. Fillion, Centre of Genomic Regulation, Spain
What Have We Learned from HIV-Barcoding Technologies?

Short Talks Chosen from Abstracts

Workshop 1 (X6)

Short Talks Chosen from Abstracts

Workshop 1 (X5)

Short Talks Chosen from Abstracts

New Insights into HIV Virology (X6)

Bryan R. Cullen, Duke University Medical Center, USA
Epitranscriptomic Regulation of HIV-1 Gene Expression
Elisabetta V. Viani-Puglisi, Stanford University, USA
Architecture of the HIV-1 Reverse Transcriptase Initiation Complex
Marina Lusic, University Clinic Heidelberg, Germany
Nuclear Architecture and HIV Integration

Short Talks Chosen from Abstracts

Insights from Recent Prophylactic Vaccine Trials (X5)

Katie Ewer, University of Oxford, UK
Lower Vaccine Doses Induce More Protective and Durable Antibody Responses Against Malaria in Clinical Trials of R21/Matrix-M.
William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Germline-Targeting Vaccine Design
Robin Shattock, Imperial College London, UK
Accelerated Experimental Medicine Trials for Iterative Vaccine Design

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 24

New Insights into Restriction Factors (X6)

Frank Kirchhoff, University of Ulm, Germany
Novel Restriction Factors Targeting HIV-1 Dependencies
Jeremy Luban, University of Massachusetts Medical School, USA
Primate Immunodeficiency Virus Proteins Vpx and Vpr Counteract Transcriptional Repression of Proviruses by the HUSH Complex
Reuben S. Harris, University of Minnesota, USA
HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-Regulators

Short Talks Chosen from Abstracts

Immunogen Design for Broadly Neutralizing Antibody Induction (X5)

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Induction of Neutralizing HIV Antibodies by Native-Like SOSIP Trimers
Max Crispin, University of Southampton, UK
The Glycan Shield of HIV-1 in Immunogen Design
Priyamvada Acharya, Duke University, USA
Structural Details of Antibody Interactions with the HIV-1 Glycan Shield and Implications for Vaccine Design
Kevin O. Saunders, Duke University, USA
Stabilized CH505 TF Env Trimer Vaccination Elicits Protective Neutralizing Antibodies in Rhesus Macaques

Short Talks Chosen from Abstracts

New Insights into HIV Latency and Reservoirs (X6)

Carine M. Van Lint, University of Brussels, Belgium
The Molecular Basis of HIV-1 Latency
Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
The Persistence of the Latent HIV Reservoirs
Maria Buzon, Vall d'Hebrón Research Institute, Spain
Characterization of the HIV Reservoir using the Single Cell FISH/flow Assay
Angela Ciuffi, Institute of Microbiology - CHUV/UNIL, Switzerland
Single Cell Transcriptomics

Short Talks Chosen from Abstracts

Inducing/Modulating Antibody Effector Functions (X5)

Hugo Mouquet, Institut Pasteur, France
Fc-Dependent Antibody Functions

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Pathogenesis and Cure (X6)

Scientific Organizers: Robert F. Siliciano, Carine M. Van Lint and Romas Geleziunas

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

HIV Vaccines (X5)

Scientific Organizers: Persephone Borrow, Georgia D. Tomaras and Rogier W. Sanders

March 22-26, 2020 • Keystone Resort • Keystone, CO, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

Global Health Travel Award Deadline: October 22, 2019 / Discounted Abstract & Scholarship Deadline: November 20, 2019 / Abstract Deadline: December 18, 2019 / Discounted Registration Deadline: January 23, 2020

Margaret E. Ackerman, Dartmouth College, USA
Engineering IgG to Alter Fcγ Receptor Dependent Function

Rasmi Thomas, U.S. Military HIV Research Program, USA
Insights from Host Genetics and Transcriptomics on Effective Vaccine Elicited Responses

Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 25

LRAs and Immunomodulatory Agents (X6)

Devi SenGupta, Gilead Sciences, Inc., USA
Immune-Based Strategies for HIV Cure

Jerome A. Zack, University of California, Los Angeles, USA
Barcoded HIV Reveals Effects of PKC Modulator on Viral Reservoir

Melanie M. Ott, Gladstone Institutes, USA
SMYD Methyltransferases are Versatile Regulators of HIV Transcription

Short Talks Chosen from Abstracts

Optimizing Germinal Center Responses for Broadly Neutralizing Antibody Induction (X5)

Antje Heit, Fred Hutchinson Cancer Research Center, USA
Immune-Profiling of Antigen-Activated Circulating and Lymph Node CD4+ T Follicular Helper Cells in HPV Vaccinated Humans

Facundo D. Batista, Ragon Institute of MGH, MIT and Harvard, USA
GC B Cell Responses

Persephone Borrow, University of Oxford, UK
Exploiting the Immunological Environment Supporting HIV-1 BnAb Induction During Infection to Inform Vaccine Design

Todd C. Bradley, Duke University Medical Center, USA
Immune Modulation of Germinal Centers During HIV-1 Vaccination

Short Talks Chosen from Abstracts

Workshop 2 (X5)

Short Talks Chosen from Abstracts

Immunotherapeutic and Gene Therapy Approaches Targeting the HIV Reservoirs (X6)

Rafick-Pierre Sekaly, Case Western Reserve University, USA
Anti-Inflammatory Cytokines Drive HIV Latency and Immune Dysfunction: Novel Targets for HIV Cure

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Gene Therapy Approaches to HIV Cure

Douglas F. Nixon, Weill Cornell Medicine, USA
The Genetics of HIV Acquisition and HIV Cure Research

Petronela Ancuta, Centre de Recherche de l'Université de Montréal, Canada

Targeting the Circadian Clock Machinery in Th17 Cells for HIV Cure/Remission Strategies

Short Talks Chosen from Abstracts

CD8 T Cell Inducing Vaccines (X5)

Louis J. Picker, Oregon Health & Science University, USA
Dissecting Mechanisms by which RhCMV-Vectored Vaccines Confer Protection

Andrew J. McMichael, Oxford University, UK
Understanding HLA-E Mediated Antigen Presentation to Inform Vaccine Design

Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 26

Therapeutic Vaccines (Joint)

Barbara K. Felber, NCI, National Institutes of Health, USA
Therapeutic Vaccines – Preclinical to Clinical Trials

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Therapeutic Vaccination Strategies

R. Brad Jones, George Washington University, USA
HIV Reservoirs Exhibit Inherent Resistance to Elimination by Cytotoxic T Cells

Julie Ake, Walter Reed Army Institute of Research, USA
MHRP Therapeutic Vaccine Strategies: Past, Present and Future

Short Talks Chosen from Abstracts

Workshop 2 (X6)

Short Talks Chosen from Abstracts

Workshop 3 (X5)

Short Talks Chosen from Abstracts

Clinical Trials (X6)

Sharon R. Lewin, University of Melbourne, Australia
Immune Checkpoint Blockers and HIV Cure Strategies

Steven G. Deeks, University of California, San Francisco, USA
Immunotherapy and HIV Control

Speaker to be Announced

Short Talk Chosen from Abstracts

Forward Vision: HIV Clinical Trials (X5)

Georgia D. Tomaras, Duke University Medical Center, USA
Interpretation of Immune Responses Elicited in Clinical Trials

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Pathogenesis and Cure (X6)

Scientific Organizers: Robert F. Siliciano, Carine M. Van Lint and Romas Geleziunas

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

HIV Vaccines (X5)

Scientific Organizers: Persephone Borrow, Georgia D. Tomaras and Rogier W. Sanders

March 22-26, 2020 • Keystone Resort • Keystone, CO, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Merck & Co., Inc.

Global Health Travel Award Deadline: October 22, 2019 / Discounted Abstract & Scholarship Deadline: November 20, 2019 / Abstract Deadline: December 18, 2019 / Discounted Registration Deadline: January 23, 2020

Fatima Laher, University of the Witwatersrand, South Africa

Durability of Vaccine-Induced Immune Responses: What the P5 Trials are Revealing

Nichole R. Klatt, University of Miami, USA

Potential Role of the Microbiome in HIV Vaccination

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
(X6)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
(X5)

FRIDAY, MARCH 27

Departure